2022 Third Quarter Conference Call

November 8, 2022 • 8:30 AM ET

NeoGenomics Hurricane Ian Emergency Response

Nov 8, 2022 • 7:00 AM EST

Q3 2022 Quarterly Results

Quarter Ended Sep 30, 2022

Third quarter 2022 consolidated revenue increased 6% to $129 million

Third quarter Clinical Services revenue increased 4% to $106 million

Pharma Services revenue increased 18% to $23 million

NeoGenomics Announces Chief Executive Officer Appointment

NeoGenomics Liquid Biopsy Subsidiary Inivata Announces New Data Demonstrating Clinical Potential of the RaDaR(TM) MRD Test in HR+ HER2- Breast Cancer

Company Profile

NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company's Pharma
Services Division serves pharmaceutical clients in clinical trials and drug development.

Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Fort Myers and Tampa, Florida; Aliso Viejo, Carlsbad and San Diego, California; Research Triangle Park, North Carolina; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; and Phoenix, Arizona; and CAP accredited laboratories in Cambridge, United Kingdom; Rolle, Switzerland; and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia. 

Latest 10-K

View Latest 10-K

NeoGenomics, Inc.

Nasdaq: NEO

Market/Symbol

Price

Change

Volume

Day Range

52 week Range

IR Contact Information

Investor Relations Bill Bonello
Chief Financial Officer
T: 239.768.0600 x2726
bill.bonello@neogenomics.com

Transfer Agent Broadridge Shareholder Services
1155 Long Island Avenue
Edgewood, NY 11717-8309
T: (888) 789-8606